Generex Announces Collaboration with NHTherapeutics to Utilize the RapidMist™ Buccal Delivery Technology for Leuprolide

Generex Biotechnology Corporation (OTCMKTS:GNBT) announced that it has entered into a Memorandum of Understanding with NHTherapeutics Inc. to co-develop a formulation for the delivery of Leuprolide into the human body through the buccal mucosa using the Generex proprietary RapidMist™buccal drug delivery system.

As quoted in the press release:

The Generex proprietary RapidMist™ drug delivery platform technology administers active pharmaceutical ingredient via aerosolized metered dose spray into the mouth for rapid absorption by the buccal mucosa.  The Company’s most advanced product in development using RapidMist™ is Generex Oral-lyn™, an insulin spray product for the treatment of diabetes mellitus.

NHTherapeutics holds intellectual property in respect to the dosing regimen and route of administration of Leuprolide and other GnRH agonists for the treatment of hypogonadism and other endocrine disorders.

Pursuant to a fee-for-service arrangement, Generex will develop a RapidMist™ formulation of Leuprolide designed to achieve the safe, simple, rapid, dose-specific, and effective administration of the active pharmaceutical ingredient into the human body via the buccal mucosa.  Thereafter, Generex will undertake local irritation and stability testing of the formulation.

It is contemplated that, pending the outcome of the RapidMist™ Leuprolide formuation data, Generex will grant to NHT a license for the global commercial exploitation of the product in the field of endocrine disorders in exchange for royalties.

Dr. Aldemar Degroot M.S., Ph.D., president and CEO of NHT, commented:

There is a real market need for a compound that can chronically increase hormonal levels, that is safe, can be easily administered, and that does not affect fertility. Unlike existing products that increase hormonal release, NHT’s lead product (NH901) is non-scheduled and will not induce supratherapeutic hormonal levels, which can result in severe adverse effects. We look forward to working with Generex to make this product a reality. Its extensive experience with the buccal delivery of peptide drugs along with its RapidMist™ technology combined with our own experience in endocrine disorders and our intellectual property are bound to lead to success.

Click here to read the full Generex Biotechnology Corporation (OTCMKTS:GNBT) press release.